MOTS-c vs Pentadeca Arginate (PDA)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

MOTS-cPentadeca Arginate (PDA)
CategoryPeptidesPeptides
Standard DoseResearch indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
TimingMorning administration preferred. Can be dosed pre-workout for enhanced exercise performance.Administer on an empty stomach. Inject near site of injury for localized effect.
Cycle Duration8-16 week cycles.4-12 weeks depending on therapeutic target.
Evidence LevelEmerging (strong preclinical)animal_plus_anecdotal
A

MOTS-c

Peptides

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

  • Injection site reactions
  • Mild fatigue post-injection
  • Transient flushing
  • Muscle soreness (exercise-mimetic effect)

Contraindications

  • Pregnancy and breastfeeding
  • Type 1 diabetes (insulin sensitivity changes require monitoring)
  • Not FDA-approved
  • Limited human safety data
  • Active cancer (metabolic pathway activation)

Best Stacking Partners

5-Amino-1MQAOD-9604Semaglutide

Mechanism

Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.

Timing

Administer on an empty stomach. Inject near site of injury for localized effect.

Cycle Duration

4-12 weeks depending on therapeutic target.

Side Effects

  • Mild nausea (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuCJC-1295/Ipamorelin

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →